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Abstract
Genetic associations between variants on chromosome 5p13 and 8q24 and gastric 
cancer (GC) have been previously reported in the Asian population. We aimed to 
replicate these findings and to characterize the associations at the genome and tran-
scriptome level. We performed a fine- mapping association study in 1926 GC patients 
and 2012 controls of European descent using high dense SNP marker sets on both 
chromosomal regions. Next, we performed expression quantitative trait locus (eQTL) 
analyses using gastric transcriptome data from 143 individuals focusing on the GC 
associated variants. On chromosome 5p13 the strongest association was observed at 
rs6872282 (P = 2.53 × 10−04) and on chromosome 8q24 at rs2585176 
(P = 1.09 × 10−09). On chromosome 5p13 we found cis- eQTL effects with an up-
regulation of PTGER4 expression in GC risk allele carrier (P = 9.27 × 10−11). On 
chromosome 8q24 we observed cis- eQTL effects with an upregulation of PSCA ex-
pression in GC risk allele carrier (P = 2.17 × 10−47). In addition, we found trans- 
eQTL effects for the same variants on 8q24 with a downregulation of MBOAT7 
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1 |  INTRODUCTION
The majority of gastric adenocarcinomas, here called gastric 
cancer (GC), is sporadic and has a multifactorial and hetero-
geneous etiology. According to its localization, GC is sub-
divided into a cardia and noncardia type and according to 
the histopathological classification of Lauren, GC is subdi-
vided into a diffuse, intestinal or mixed type.1 On the etiolog-
ical level, inflammation represents an important risk factor, 
which is mainly caused by Helicobacter pylori (H. pylori) 
infection.1
In multifactorial diseases, genome- wide association stud-
ies (GWAS) have systematically led to the identification of 
risk loci involved in disease etiology. Accordingly, GWAS in 
GC have been carried out in the Asian population, which have 
led to the identification of risk loci on chromosome 1q22, 
3q13, 5p13, 6p21, 7p15, 8q24, and 10q23.2-6 The risk loci 
on 5p137 and 8q248,9 have been confirmed to contribute to 
GC development also in the European population. However, 
functional data on the underlying risk genes and on disease 
conferring pathomechanisms at these loci are scarce. Thus, 
we aimed to further confirm the role of 5p13 and 8q24 in the 
etiology of GC in Europeans and to characterize the associ-
ations on the genome and transcriptome level. However, it 
should be noted, that the locus on chromosome 1q22 was also 
independently replicated in an European GC sample under 
certain genetic models (dominant and recessive).10 Because 
no allelic association tests were presented in this study we did 
not follow up the association at the 1q22 locus.
2 |  MATERIALS AND METHODS
2.1 | Samples
For the fine- mapping association study at 5p13 and 8q24, 
we used a sample consisting of 1926 histopathologically 
confirmed GC patients (680 females, 1246 males) and 2012 
ethnically matched controls (985 females, 1027 males) that 
were not screened for the presence of GC. All study subjects 
were of European descent and were recruited at four different 
study sites in Latvia, Lithuania, Spain and Germany. Table 
S1 provides sample details, including origin of samples and 
distribution of GC localization (cardia, noncardia) as well as 
Lauren type (diffuse, intestinal, and mixed). Informed con-
sent was obtained from all participants and approval was ob-
tained from the ethic board of each participating site.
The expression quantitative trait locus (eQTL) analysis 
was based on 143 individuals of German descent (15 females, 
128 males). All subjects were histopathologically diagnosed 
with intestinal metaplasia of the distal esophagus (Barrett’s 
esophagous) and additionally, endoscopic biopsies of the 
gastric cardia were obtained during routine surveillance gas-
troscopies. Absence of pathological changes and H. pylori 
infection in the gastric mucosa was histopathologically con-
firmed for all cases. Informed consent was obtained from all 
participants as well as approval from the responsible ethic 
board.
2.2 | Genotyping and expression analyses
For the fine- mapping association study on 5p13 and 8q24, 
single- nucleotide polymorphisms (SNPs) were selected for 
genotyping with the aim to impute a maximum number of ge-
netic variants within both regions. To define the regions of in-
terest the main recombination hotspots flanking both loci were 
determined using Haploview Version 4.2 and the HapMap 
dataset III (Release August 2010).11 Next, all SNPs with a 
minor allele frequency (MAF) of ≥5% on Illumina Human 
Core Exome Chip were used to reduce the number of necessary 
tagging SNPs within both regions. To prove that these SNPs 
cover the regions sufficiently an imputation on a genome- wide 
genotyped test data set12 was performed. Finally, we used the 
test data set and ensured that all common publicly released 
SNPs within both regions were imputed with high imputation 
quality scores (INFO > 0.4). This resulted in 14 SNPs located 
within 5p13 and 6 SNPs within 8q24 (Table 1) as tagging 
markers for the respective loci. All 20 SNP markers were gen-
otyped using a Sequenom MassARRAY iPlex Gold® system 
(Sequenom, San Diego, CA, USA). For quality control (QC), 
expression in GC risk allele carrier (P = 3.11 × 10−09). In summary, we confirmed 
and refined the previously reported GC associations at both chromosomal regions. 
Our data point to shared etiological factors between Asians and Europeans. 
Furthermore, our data imply an upregulated expression of PTGER4 and PSCA as 
well as a downregulated expression of MBOAT7 in gastric tissue as risk- conferring 
GC pathomechanisms.
K E Y W O R D S
eQTL study, gene expression, genetic association study, stomach neoplasms
in your future”), and CIBER de enfermedades 
hepáticas y digestivas (CIBERehd).
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intra- and interplate duplicates were included. Furthermore, 
negative controls (H2O) were added to each 384 well plate 
in order to exclude contamination. Cluster plots of all SNPs 
were visually checked and manually corrected if necessary. 
The postgenotype QC comprised the exclusion of SNPs with 
Hardy- Weinberg equilibrium (HWE) P < 1 × 10−04 in con-
trols and P < 1 × 10−06 in patients, a call rate (CR) < 95% 
as well as exclusion of samples with a CR < 90%. A sin-
gle marker (rs138377917 on chromosome 8q24) failed QC. 
Detailed information on primer sequences, genotyping and 
genotype calling is available upon request.
For the eQTL analysis DNA from 143 donors 
was extracted from peripheral blood and genotyped 
genome- wide using Human OmniExpress- v1.1 and 
HumanOmniExpressExome- v1.2 BeadChips (Illumina, San 
Diego, CA, USA). The postgenotype QC comprised the exclu-
sion of SNPs with HWE P < 1 × 10−05, minor allele frequency 
(MAF) <5% or a CR < 98% as well as the exclusion of sam-
ples with a CR < 99%. For the expression analysis, total RNA 
from gastric cardia biopsies was isolated using the AllPrep 
DNA/RNA Mini Kit (Qiagen, Hilden, Germany). The tran-
scriptome was assessed using the HumanHT- 12v4 Expression 
BeadChip (Illumina) that targets more than 48 000 transcripts 
in the refseq database (Build 36.2, release 22). Only probes 
with a Pdetection < 0.01 in more than 5% of the samples were 
included for analysis. Furthermore, all probes were filtered for 
unique alignment and quality. Probes classified with a perfect 
or good quality as reported in the R package illuminaHu-
manv4.db were considered for further analysis.
2.3 | Fine- mapping and eQTL analyses
For the fine- mapping association analysis, all genotyped SNPs 
were used for the imputation of additional markers at both re-
gions. For this purpose, IMPUTE213 was used utilizing the 1000 
Genomes Phase 3 data as reference.14 After imputation, all SNPs 
with an info score >0.7 were further processed, which resulted 
in 478 SNPs on 5p13 and 315 SNPs on 8q24. For each of the 
four study sites, association analysis of genotyped and imputed 
SNPs was performed by SNPTEST v2.5.15 A fixed- effects meta- 
analysis was performed to combine the results across study sites. 
We additionally performed genotype- phenotype (GxP) analyses 
and stratified our cases according to tumor localization (cardia, 
noncardia) as well as histopathological Lauren type (diffuse, in-
testinal, or mixed). Moreover, pairwise linkage disequilibrium 
(LD) between markers was determined using SNAP16 and the 
1000 Genomes Pilot 1 data from the European population.14
For the eQTL analysis genotypes of 568 265 autosomal 
SNPs and expression intensity data from 11 900 probes 
were used from all 143 probands. The expression data 
were quantile normalized and eQTLs were mapped using a 
linear regression model implemented in the MatrixEQTL 
R package.17 The associations were corrected for the top 
five principal components and eQTL effects with a false 
SNP Chr Allelea RR (95% CI) Combined P- value
rs7716982 5 G/T 1.06 (0.96- 1.16) 2.31 × 10−01
rs6893430 5 C/T 1.15 (1.03- 1.29) 1.20 × 10−02
rs6861121 5 A/G 1.07 (0.94- 1.23) 3.07 × 10−01
rs7726237 5 G/A 1.12 (1.02- 1.23) 1.89 × 10−02
rs10737963 5 C/A 1.08 (0.97- 1.19) 1.60 × 10−01
rs12523329 5 C/T 1.06 (0.96- 1.17) 2.79 × 10−01
rs1002424 5 A/G 1.16 (1.05- 1.29) 3.09 × 10−03
rs257009 5 C/T 1.09 (0.99- 1.20) 8.39 × 10−02
rs10053664 5 C/T 1.06 (0.97- 1.16) 2.23 × 10−01
rs13361707 5 C/T 1.17 (1.06- 1.29) 2.29 × 10−03
rs3805486 5 A/G 1.13 (0.99- 1.29) 6.20 × 10−02
rs462366 5 T/C 1.04 (0.94- 1.15) 4.28 × 10−01
rs6876367 5 C/T 1.12 (1.01- 1.24) 2.70 × 10−02
rs2291782 5 A/G 1.06 (0.96- 1.16) 2.57 × 10−01
rs2976400 8 A/G 1.04 (0.95- 1.15) 3.70 × 10−01
rs2976392 8 A/G 1.29 (1.18- 1.41) 2.14 × 10−08
rs2976397 8 T/G 1.30 (1.19- 1.42) 7.18 × 10−09
rs12155758 8 A/G 1.24 (1.13- 1.37) 1.03 × 10−05
rs1435453 8 C/T 1.23 (1.12- 1.34) 6.98 × 10−06
Chr, chromosome; CI, confidence interval; RR, relative risk.
aThe underlined allele represents the GC risk allele.
T A B L E  1  Case- control comparison 
(1926 GC cases, 2012 controls) of 
genotyped SNPs at chromosomal regions 
5p13 and 8q24. One marker (rs138377917 
on chromosome 8q24) failed QC and is not 
shown
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discovery rate (FDR) of <0.05 were considered as signif-
icant. In addition, eQTLs with a distance of <1 Mb to the 
corresponding probes were considered as cis- regulatory 
variants. Vice versa, SNPs with a distance of >1 Mb to 
the corresponding probes were classified as trans- eQTLs.
3 |  RESULTS
3.1 | Association and eQTL findings on 
chromosome 5p13
Of all genotyped SNPs at 5p13 5 variants showed significant 
GC association (Table 1). Table S2 shows the association 
findings within each study site. The strongest associa-
tion in the entire sample was observed for rs13361707 
(P = 2.29 × 10−03, RR = 1.17 (95% CI = 1.06- 1.29)). The 
fine- mapping at this region included 478 imputed SNPs, 
of which 28 showed GC association. The strongest asso-
ciation was observed for rs6872282 (P = 2.53 × 10−04, 
RR = 1.22 (95% CI = 1.09- 1.35), risk allele C, oppo-
site allele T, see Table S3). Of note, rs13361707 and 
rs6872282 are in high LD with r2 = 0.92. Figure 1A pro-
vides the regional association plot at 5p13 and shows that 
all associated variants encompass the coding regions of the 
genes PTGER4, TTC33, and PRKAA1. The GxP analysis 
at 5p13 using GC tumor localization and histopathological 
Lauren type as strata did not lead to an association im-
provement. Table S4 shows all GxP results for rs6872282, 
the strongest associated marker in the entire analysis. In 
addition, a conditional analysis using rs6872282 did not 
F I G U R E  1  Regional association plots 
of GC associations at chromosome 5p13 (A) 
and chromosome 8q24 (B). SNP association 
results are shown as - log P. The most 
significant associated SNP—rs6872282 at 
5p13 (A), rs2585176 at 8q24 (B)—is shown 
as solid diamond. Pair- wise correlation (r2) 
between the most significant associated 
SNP and the other SNPs in a 500 kb 
flanking region is illustrated by the color 
scheme. The blue spikes show the estimated 
recombination rates. All annotated genes in 
both regions are shown at the bottom and 
their reading direction is given by arrows
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reveal any independent disease association (P > 0.5, data 
not shown).
The eQTL analysis at 5p13 was initially restricted to SNPs 
with r2 > 0.8 to the most associated GC variant and revealed 
cis- eQTL effects for the expression of PTGER4 in gastric 
tissue (P = 9.27 × 10−11 for rs10074991). Here, an upregu-
lated expression of the transcript was observed in GC risk 
allele carrier (Figure 2A). We then tested all 5p13 SNPs for 
PTGER4 eQTL effects, which revealed that rs10074991 rep-
resents the strongest eQTL for the expression of PTGER4 at 
this locus. Finally, we did not observe any trans- eQTL effects 
using GC associated risk variants at 5p13 and an FDR < 0.05.
3.2 | Association and eQTL findings on 
chromosome 8q24
Of all genotyped SNPs at 8q24 4 variants showed significant 
GC association (Table 1). Table S2 shows the association find-
ings within each study site. The strongest association in the 
entire sample was observed for rs2976397 (P = 7.18 × 10−09, 
RR = 1.30 (95% CI = 1.19- 1.42)). The fine- mapping at 8q24 
included 315 imputed SNPs. Of them 42 SNPs showed GC 
association with rs2585176 being the most associated variant 
(P = 1.09 × 10−09, RR = 1.34 (95% CI = 1.22- 1.47), risk al-
lele T, opposite allele A, see Table S3). Notably, rs2976397 
and rs2585176 are in high LD with r2 = 0.90. Figure 1B shows 
the regional association plot at 8q24 and shows that all associ-
ated variants are located close to the genes JRK, PSCA, and 
LY6K. The GxP analysis at 8q24 using GC tumor localization 
and histopathological Lauren type as strata did not lead to the 
identification of a particular GC subtype with predominant as-
sociation. Table S5 shows all GxP results for rs2585176, the 
strongest associated marker in the entire analysis. In addition, 
a conditional analysis using rs2585176 did not reveal any in-
dependent disease association (P > 0.5, data not shown).
The eQTL analysis at 8q24 was initially restricted to 
SNPs with r2 > 0.8 to the most associated GC variant and 
revealed cis- eQTL effects for the expression of PSCA 
(P = 2.17 × 10−47). The lead eQTL is rs2920283 and an up-
regulated PSCA expression in gastric tissue was observed in 
GC risk allele carrier (Figure 2B). As for 5p13, we then tested 
all 8q24 SNPs for PSCA eQTL effects, which revealed that 
rs2920283 represents the strongest eQTL for the expression 
of PSCA at this locus. Finally, we tested for trans- eQTL ef-
fects using GC associated risk variants at 8q24 with r2 > 0.8 
to the lead GC SNP. Here, we observed a regulatory effect for 
the expression of MBOAT7 in gastric tissue, which is located 
on chromosome 19q13. The most significant trans- eQTL was 
rs2294008 (P = 1.99 × 10−09) and led to a downregulated ex-
pression of MBOAT7 in GC risk allele carrier [Figure 2C]. 
Notably, the lead cis- and trans- eQTLs are in perfect LD 
(r2 = 1.00) pointing to a common regulatory effect. However, 
it should be noted that the statistical significance of the cis- 
eQTL is much higher than for the trans- eQTL.
4 |  DISCUSSION
The GC associations at 5p13 and 8q24 have been initially 
reported in the Asian population.2,4 It has subsequently 
F I G U R E  2  eQTL effects for GC associated variants at chromosomal regions 5p13 and 8q24. Log2 gene expression, error bars for median 
log2 expression and standard deviation are shown as box plot (y axis) sorted by SNP genotype (x- axis) with the common allele on the left. The 
individual log2 gene expression is indicated by small dots in blue (y- axis). A, cis- eQTL (rs10074991, risk allele G) for the expression of PTGER4 
at 5p13 (P = 9.27 × 10−11, regression slope (β) = −56.18). B, cis- eQTL (rs2920283, risk allele C) for the expression of PSCA (P = 2.17 × 10−47, 
β = 3958.10). C, trans- eQTL (rs2294008, risk allele T) for the expression of MBOAT7 (P = 1.99 × 10−09, β = −40.57)
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been shown that both loci also play a role in GC etiology 
in European populations.7-9 In the present study, we aimed 
to further replicate the GC association in the largest so far 
analyzed European cohort as well as to refine and character-
ize the association signals on the genome and transcriptome 
level.
On chromosome 5p13 all GC associated variants 
were in high LD (r2 > 0.8) to the most associated marker 
(rs6872282) and in high LD (r2 > 0.8) to all risk SNPs previ-
ously reported at this locus in Asians2,18-23 and Europeans.7 
Thus, together with previous findings, our data provide ev-
idence that one or more of these SNPs represent(s) the true 
GC conferring variant(s) in both the Asian and European 
population. Of the implicated SNPs rs3805495 is in per-
fect LD to the leading GC risk variant rs6872282 (r2 = 1) 
and represents an interesting functional SNP. According to 
RegulomeDB24 this variant is predicted to alter motifs for 
several transcription factors and to affect histone modifi-
cation in digestive tissues including gastric mucosa. In ad-
dition, we found that the GC risk alleles of the associated 
SNPs lead to an upregulated PTGER4 expression in gastric 
tissue, which represents a plausible GC pathomechanism at 
this locus. To our knowledge, this eQTL effect has not been 
reported so far and thus needs further replication in inde-
pendent gastric tissue samples.
Also on the functional level, PTGER4 represents an in-
teresting candidate for GC. The gene encodes the prostaglan-
din E2 (PGE2) receptor 4 (EP4), which mediates cellular 
responses to PGE2. PGE2 is derived from arachidonic acids 
through the enzymatic activity of cyclooxygenase- 2 (COX- 
2). It has already been shown that the COX- 2/PGE2 pathway 
plays a key role in generation of the inflammatory microen-
vironment in GC and represents a downstream effector of 
Toll- like receptor (TLR) activation that is—among others—
triggered through H. pylori infection,25 the most prominent 
environmental GC risk factor. Interestingly, one study with 
H. pylori positive and negative GC cases and controls found 
a gene- environment interaction between 5p13 risk SNPs and 
H. pylori infection that showed association with GC.18
Genetic variability at 5p13 also contributes to other dis-
eases with inflammatory components, including Crohn’s 
disease,26-31 ulcerative colitis,32-34 ankylosing spondylitis35 
and multiple sclerosis.36-38 Furthermore, cis- regulatory ef-
fects involving the expression of PTGER4 in some of these 
traits have been described previously in lymphoblastoid cell 
lines.39 However, all SNPs and eQTLs implicated in these 
studies are only in weak LD (r2 < 0.3) to the GC variants 
and PTGER4- eQTLs identified in the present study (see 
Table S6). The findings point to PTGER4 as risk gene for 
different diseases with inflammatory components. However, 
more complex pathomechanisms with disease- and/or tissue- 
specific effects on the PTGER4 expression regulation seem 
to be present at this locus.
On chromosome 8q24 all GC associated variants were in 
high LD (r2 > 0.8) to the most associated marker (rs2585176) 
and in high LD (r2 > 0.8) to all risk SNPs previously reported 
at this locus in Asians and Europeans (summarized in Ref. 
40). As for 5p13, this provides evidence that shared etio-
logical factors between Asians and Europeans contribute to 
GC risk at this locus and that one or more of the identified 
SNPs represent(s) the true GC conferring variant(s). Of the 
implicated SNPs rs2294008 (C>T, Met1Thr) represents an 
interesting functional variant, which is located in the trans-
lation starting site of PSCA, is in high LD (r2 = 0.86) with 
the lead GC SNP and also the strongest trans- eQTL for the 
expression of MBOAT7 (see below). This SNP leads to an 
alternative PSCA splice form on the protein level41 and thus 
has been favored as true GC risk variant at this locus. In ad-
dition, rs2585183 represents an interesting functional variant 
according to RegulomeDB.24 The variant is in high LD to the 
leading GC risk SNP (r2 = 0.90) and is predicted to affect 
histone modification in digestive tissues including gastric 
mucosa.
Moreover, we found that the risk alleles of the GC asso-
ciated markers lead to an upregulated expression of PSCA. 
The presence of this eQTL in gastric tissue is supported 
by GTEx (version 7, dbGaP accession phs000424.v7.p2), 
where the strongest eQTL in our study (rs2920283) shows 
cis- regulatory effects for PSCA with P = 8.1 × 10−33. 
Furthermore, cis- eQTL effects involving the presented vari-
ants and PSCA have been shown previously in healthy gastric 
and gastric tumor tissue.42 Thus, the PSCA eQTL has been 
independently validated and represents a plausible GC path-
omechanism at 8q24.
Also on the functional level PSCA represents an inter-
esting candidate for GC development. The gene encodes a 
glycosylphosphatidylinositol- anchored cell- surface protein 
with highest expression in tumor cells and seems to play 
a role in multiple cellular processes, including immune- 
modulation, cell adhesion, proliferation and survival.43 The 
PSCA risk alleles of the GC associated SNPs also mediate 
risk for chronic atrophic gastritis,9,44 an H. pylori - induced 
precursor lesion of GC. In contrast, the opposite alleles at 
the same variants lead to duodenal ulcer,41,44-46 which is 
also induced by H. pylori infection, but characterized by 
severe antral mucosa inflammation and protective GC ef-
fects.47-49 Thus, it has been hypothesized that gastric H. py-
lori infection leads to chronic atrophic gastritis and GC in 
patients with GC risk alleles at PSCA variants, whereas 
carrier of the opposite alleles tend to develop severe antral 
mucosa inflammation and duodenal ulcer.41,44-46
The same regulatory variants on 8q24 that represent cis- 
eQTLs for the expression of PSCA lead to a downstream 
downregulated MBOAT7 expression in gastric tissue, which 
suggests that MBOAT7 might be also of relevance in GC 
etiology. Interestingly, MBOAT7 encodes an enzyme with 
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lysophosphatidylinositol acyltransferase activity and has 
been implicated in anti- inflammatory processes through the 
regulation of arachidonic acid- derived prostaglandin (PG) 
levels.50 Recently, it has been shown that MBOAT7 plays 
a pivotal role in hepatic inflammation and fibrosis in pa-
tients with hepatitis C infection51 and alcohol- related liver 
cirrhosis.52 Thus, MBOAT7 might also contribute to GC 
susceptibility via biological pathways that are involved in 
inflammation. However, although the expression of PSCA 
and MBOAT7 is regulated by the same SNPs, a cellular 
connection between them has not been described so far.
In conclusion, our study has confirmed the role of 5p13 
and 8q24 in the etiology of GC in Europeans and has char-
acterized the associations on the genome and transcrip-
tome level. Whereas the eQTL effect of PSCA has been 
described before, the eQTL effects involving PTGER4 
and MBOAT7 have not been described before in the con-
text of GC. Future work is now required as to whether the 
same eQTL effects are present in the remaining gastric re-
gions or other tissues with relevance in GC development. 
Additionally, functional work is required to prove that the 
observed eQTL effects play a role in GC development 
rather than represent epiphenomena with no relevance for 
GC development. In this context, our fine- mapping asso-
ciation and eQTL study with altered gastric expression of 
PTGER4, PSCA, and MBOAT7 in GC risk allele carriers 
may serve as impetus.
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